SCHEMBL8524209

SCHEMBL8524209

Clc1cc(/C=C\CN2CCC3(CCCCC3)CC2)ccc1C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.51
TMEM97 Q5BJF2 1/20 0.51
EBP Q15125 1/20 0.51
HTR1A P08908 3/20 0.38
ADRA1B P35368 3/20 0.38
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
LTA4H P09960 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
GPR183 P32249 2/20 0.34
MCHR1 Q99705 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494033 1.00 SIGMAR1 (0.51) SIGMAR1TMEM97EBPHTR1AADRA1B
SCHEMBL25317113 1.00 SIGMAR1 (0.51) SIGMAR1TMEM97EBPHTR1AADRA1B
Hydrochloric Acid SCHEMBL7324536 0.99 SIGMAR1 (0.50) SIGMAR1TMEM97EBPHTR1AADRA1B
Hydrochloric Acid SCHEMBL7324525 0.99 SIGMAR1 (0.50) SIGMAR1TMEM97EBPHTR1AADRA1B
Hydrochloric Acid SCHEMBL7324521 0.99 SIGMAR1 (0.50) SIGMAR1TMEM97EBPHTR1AADRA1B
SCHEMBL8330431 0.89 SIGMAR1 (0.43) SIGMAR1TMEM97EBPHTR1AADRA1B
SCHEMBL8330429 0.89 SIGMAR1 (0.43) SIGMAR1TMEM97EBPHTR1AADRA1B
SCHEMBL7310895 0.88 SIGMAR1 (0.57) SIGMAR1TMEM97EBPGAAPSEN1
SCHEMBL6263930 0.88 SIGMAR1 (0.57) SIGMAR1TMEM97EBPGAAPSEN1
SCHEMBL11630013 0.88 SIGMAR1 (0.57) SIGMAR1TMEM97EBPGAAPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0917464-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1999-05-26 EP claimed
WO-1998004251-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1998-02-05 WO claimed
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
EP-4213822-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS Therapeutics (FR) 2023-07-26 EP disclosed
WO-2022058533-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS ACE, HAVCR2, FURIN SIGMAR1 3429/4885TMEM97 3055/4885EBP 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.